Sentence examples for multiple therapeutics from inspiring English sources

The general strategy presented herein can potentially be utilized for the preparation of polymeric vehicles that are capable of delivering multiple therapeutics under controlled individual release kinetics.

To address these issues, recent efforts have been devoted to developing nanocarriers that can efficiently deliver multiple therapeutics with controlled release properties and increased tumor deposition.

These multifunctional, hybrid architectures possess better attributes for drug delivery such as high loading capacity, improved stability, ease of anchoring ligands, surface manipulation, tuneable drug release, loading multiple therapeutics, and excellent in vivo performance.

In developing new generations of coatings for medical devices and tissue engineering scaffolds, there is a need for thin coatings that provide controlled sequential release of multiple therapeutics while providing a tunable approach to time dependence and the potential for sequential or staged release.

Multiple therapeutics, including drugs, anti-inflammatory interleukin-10 gene therapy, antibiotics, and mesenchyme stromal cells, have been tested for efficacy in EVLP [32 35].

Although no FDA-approved therapies currently exist for the Notch pathway, multiple therapeutics (e.g., demcizumab, tarextumab, GSI MK-0752, R04929097, and PF63084014) have been developed to target different aspects of this pathway for both hematologic and solid malignancies.

Sequential manufacturing of multiple biological therapeutics from individual strains requires rapid changes to their environment in high-density cell cultures.

The new generation of multiple sclerosis therapeutics includes fingolimod (Novartis Pharmaceuticals) and cladribine (Merck Serono), that are in a more advanced stage of development.

Multiple different therapeutics are in clinical development, so it is important to consider whether different therapeutic approaches lend themselves to specific oncogenic aberrations.

In this report, we focus on phosphoinositide signaling mediated by the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that is overexpressed in a variety of solid tumors and is the target for multiple cancer therapeutics.

As recovery following acute optic neuritis often is incomplete, with residual deficits in low-contrast vision, colour vision, vision-specific quality of life, and sometimes high-contrast visual acuity (HCVA) (Cole et al., 2000; Optic Neuritis Study Group, 2004, 2008 b ), more effective treatment of optic neuritis is itself an area of unmet need in multiple sclerosis therapeutics.